Want to see HK:2511 full AI Analyst Report?
2511 Stock Chart & Stats
HK$3.05
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.05
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.80 - HK$4.72
Previous CloseN/A
Volume82.00K
Average Volume (3M)1.41M
Market Cap
HK$1.71B
Enterprise ValueHK$1.15K
Total Cash (Recent Filing)HK$502.94M
Total Debt (Recent Filing)HK$126.92M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairThe return to positive equity and more manageable leverage improves financial resilience versus 2021–2022. This gives Hightide greater flexibility to fund development, although continued losses could reverse the improvement.
Reduced Cash-flow DeficitA smaller free-cash-flow deficit suggests some improvement in cash discipline or development spending. If sustained, this could extend the company’s funding runway, though cash generation remains negative and external financing is still required.
Reported EPS ImprovementThe reported EPS growth indicates a year-over-year improvement in per-share earnings performance. However, its long-term significance is limited while the company remains loss-making and has not yet established recurring commercial revenue.
Bears Say
No Reported RevenueZero reported revenue means Hightide has not yet demonstrated commercial traction or a self-funding business model. Until products generate recurring sales, results will remain dependent on development progress and access to external capital.
Persistent Operating LossesRecurring EBIT and net losses show that the company has no established operating leverage. Continued losses can erode equity, increase financing needs, and delay the point at which the biotechnology platform becomes economically sustainable.
Ongoing Cash BurnPersistent negative operating and free cash flow indicates that core activities consume capital rather than generate it. This creates long-term funding dependence and exposes shareholders to dilution or higher financial risk if commercialization is delayed.
Hightide Therapeutics Inc News
2511 FAQ
What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$1.71B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
Hightide Therapeutics Inc’s upcoming earnings report date is Aug 31, 2026 which is in 11 days.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -HK$0.268 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Overvalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 571,325,700 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.268 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hightide Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
Technical Analysis
CANbridge Pharmaceuticals Inc.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Cutia Therapeutics
―